U.S. Gas Utilities Stock News

If you are wondering whether Digi International's current share price lines up with its underlying worth, this piece will walk through the key valuation checks that matter most. The stock last closed at US$48.82, with recent returns of 8.7% over 30 days, 13.1% year to date and 59.9% over 1 year, alongside a 2.7% decline over the past week and a 174.7% return over 5 years. Recent news coverage has focused on Digi International's position as a provider of connectivity and IoT solutions and how...

Steven Madden (NasdaqGS:SHOO) reported Q4 2025 results that came in above its prior guidance. The quarter featured strong performance in its core footwear business and the recently acquired Kurt Geiger brand. The company recorded an impairment on intangible assets related to its portfolio. Management cited ongoing U.S. tariff policy challenges and chose not to issue earnings guidance for 2026. Steven Madden, a well known name in branded footwear and accessories, sits at the intersection of...

Crescent Biopharma (CBIO) closed out FY 2025 with Q4 revenue of US$10.8 million, basic EPS of a US$3.35 loss, and a net loss of US$92.4 million. Its trailing twelve month revenue was US$10.8 million, with basic EPS of a US$5.59 loss and a total net loss of US$153.9 million. The company’s quarterly revenue moved from US$0 in the first three quarters of FY 2025 to US$10.8 million in Q4. Over the same period, quarterly basic EPS moved from a US$18.39 loss in Q1 to a US$4.93 loss in Q2, a US$1.27...

If you are looking at Federal Signal and wondering whether the recent share price puts it at a fair level or not, this article walks through what the current market price might be implying about value. The stock last closed at US$116.43, with a 1.9% decline over the past 7 days, a 6.8% gain over 30 days, a 4.5% return year to date, 44.1% over 1 year, 110.5% over 3 years, and 225.3% over 5 years. Recent news around Federal Signal has largely focused on its position in specialized vehicles and...

MGP Ingredients, Inc. has reported past fourth-quarter 2025 results showing sales of US$138.32 million and a net loss of US$134.63 million, driven largely by a very large US$152.62 million goodwill and intangible asset impairment in its Branded Spirits segment. For 2025 as a whole, the company moved from net income to a net loss, while simultaneously closing a US$117.17 million common stock shelf registration, maintaining a quarterly dividend of US$0.12 per share, and issuing 2026 sales...

If you are looking at AtriCure and wondering whether the current share price reflects its true worth, you are not alone. Many investors are asking the same question right now. The stock recently closed at US$31.25, with returns of a 4.1% decline over 7 days, a 17.3% decline over 30 days and a 20.4% decline year to date, adding to a 19.3% decline over 1 year, a 21.7% decline over 3 years and a 51.0% decline over 5 years. These moves have put more attention on how AtriCure is being valued,...

Ramaco Resources reported fourth-quarter 2025 sales of US$128.01 million and a net loss of US$14.71 million, alongside a full-year 2025 net loss of US$51.45 million on sales of US$536.62 million, while also being served with a putative securities class action tied to disclosures about its Brook Mine rare earth project. At the same time, the company outlined progress at Brook Mine and highlighted stronger liquidity following recent financings, underlining how its rare earth ambitions and...

PROCEPT BioRobotics (NasdaqGM:PRCT) has overhauled its commercial model, implementing a major realignment of its sales organization and pricing strategy. The company has removed bulk purchase discounts and created a dedicated team focused on driving greater procedural adoption. These changes come alongside significant procedure growth and a reset in financial guidance, marking a key shift in how the company pursues profitability and market expansion. PROCEPT BioRobotics focuses on robotic...

If you are wondering whether Southwest Gas Holdings at around US$88 per share offers good value today, you are not alone; many investors are trying to work out what a fair price looks like. The stock has returned 0.7% over the last week, 7.6% over the past month, 10.0% year to date, 21.3% over one year, 62.5% over three years and 51.5% over five years, which naturally raises questions about how its current price lines up with its fundamentals. Recent news flow around regulated utilities, gas...

Xylem (NYSE:XYL) has authorized a new share repurchase program of up to $1.5b. The program allows the company to buy back shares opportunistically over time. The announcement comes with Xylem shares recently trading around $129.56. Xylem, trading on the NYSE under the ticker XYL, is moving ahead with a sizeable $1.5b buyback plan at a share price of about $129.56. Over the past 3 years, the stock has returned 29.3%, and 37.1% over 5 years, which gives context for how management is choosing...

Xenon Pharmaceuticals (XENE) has put fresh numbers on the table for FY 2025, with first half revenue at US$7.5 million and a basic EPS loss of US$1.90, alongside a trailing twelve month EPS loss of US$4.36. The company has seen revenue move from US$0 in both halves of 2024 to US$7.5 million in the latest half. Basic EPS losses widened from US$1.36 and US$1.64 in the first and second halves of 2024 to US$1.90 most recently and a trailing twelve month net loss of US$345.91 million, keeping...

American Healthcare REIT (AHR) has wrapped up FY 2025 with Q4 revenue of US$604.1 million and basic EPS of US$0.06, rounding out a trailing twelve month picture that shows total revenue of about US$2.3 billion and basic EPS of US$0.42. Over the past few quarters the REIT has seen revenue move from US$540.2 million in Q4 2024 to US$604.1 million in Q4 2025, while quarterly EPS shifted from a loss of US$0.20 per share to a profit of US$0.06 per share. This sets up a year where investors will be...

GoodRx Holdings (GDRX) is back in focus after launching its Employer Direct platform to help companies reduce high-impact brand drug costs, alongside 2025 earnings, fresh 2026 guidance, and a cluster of analyst rating changes. See our latest analysis for GoodRx Holdings. GoodRx’s recent earnings update, 2026 revenue guidance and the Employer Direct launch have been followed by a sharp reset in sentiment, with a 7 day share price return of 24.29% decline and a 1 year total shareholder return...

Burford Capital (NYSE:BUR) rounded out FY 2025 with Q4 revenue of US$33.4 million and a basic EPS loss of US$0.17, as quarterly earnings swung back into the red despite a profitable first half. The company has seen quarterly revenue move from US$244.9 million and EPS of US$0.62 in Q3 2024 to US$178.0 million and EPS of US$0.40 in Q2 2025, and then to US$64.7 million with an EPS loss of US$0.09 in Q3 2025 before landing at the latest Q4 figures. This sets up a results season in which investors...

If you are wondering whether Thermon Group Holdings is still attractively priced or already reflecting most of its potential, you are in the right place for a valuation-focused look at the stock. The share price, last closing at US$50.78, comes with a mixed return profile, with a 0.5% decline over 7 days, a 16.9% gain over 30 days, 34.9% year to date, 72.1% over 1 year, 84.6% over 3 years and 136.7% over 5 years. Recent price action sits alongside ongoing news flow around Thermon Group...

D-Market Elektronik Hizmetler ve Ticaret (NasdaqGS:HEPS) has wrapped up FY 2025 with Q4 revenue of approximately ₺30.3b and a net loss of about ₺3.2b, capping a year in which trailing twelve month revenue reached roughly ₺84.7b alongside a total net loss of around ₺5.7b. The company reported quarterly revenue increasing from about ₺20.4b in Q4 2024 to ₺30.3b in Q4 2025, while quarterly net losses widened from roughly ₺724m to about ₺3.2b over the same period. EPS on a trailing twelve month...

MannKind (MNKD) has wrapped up FY 2025 with fourth quarter revenue of US$112 million and a basic EPS loss of US$0.05, setting a clear focal point for investors watching how its income statement is evolving. Over recent periods the company has seen revenue move from US$70 million in Q3 2024 to US$82 million in Q3 2025, while quarterly EPS has ranged from US$0.04 in Q1 2025 to a small profit of US$0.03 in Q3 2025 before this latest loss. This puts the spotlight firmly on how durable its margins...

Alexander & Baldwin (ALEX) has wrapped up FY 2025 with fourth quarter revenue of US$43.8 million and basic EPS of US$0.05, alongside trailing twelve month revenue of US$206.7 million and EPS of US$0.89. Over the last six quarters, the company has seen quarterly revenue move from US$63.2 million in Q4 2024 to US$56.8 million in Q1 2025 and down to US$43.8 million in Q4 2025, while quarterly EPS moved from US$0.18 to US$0.29 and then US$0.05. This sets up a mixed backdrop for a stock trading at...

Golden Entertainment (GDEN) has wrapped up FY 2025 with Q4 revenue of US$155.6 million and a basic EPS loss of US$0.33, alongside net income excluding extra items of a US$8.5 million loss. Over recent periods, the company has seen quarterly revenue move between US$154.8 million and US$164.2 million, while EPS has swung from a profit of US$0.18 in Q3 2024 to a loss of US$0.33 in Q4 2025. This leaves investors watching how quickly margins can stabilize from here. See our full analysis for...

Latest Earnings Snapshot Medical Properties Trust (MPW) has wrapped up FY 2025 with fourth quarter revenue of US$294.5 million, basic EPS of US$0.03, and Funds From Operations of US$115.9 million, giving investors a cleaner read on cash based performance for a healthcare REIT. The company has seen revenue move from US$247.5 million in Q3 2024 to US$234.8 million in Q4 2024 and then to US$294.5 million in Q4 2025. Basic EPS shifted from a loss of US$0.69 in Q4 2024 to a loss of US$0.20 in Q1...

A Kinsale Capital Group (NYSE:KNSL) board director recently sold shares, drawing fresh attention to insider activity at the company. Management has flagged moderating premium growth and increasing competition in its core markets. Together, these updates point to a changing operating backdrop that investors are now reassessing. Kinsale Capital Group, trading at $389.67 as of the last close, comes into this news with a mixed recent record. The stock is up 4.4% over the past week, flat over...

Neptune Insurance Holdings (NP) closed FY 2025 with Q4 revenue of US$43.8 million and basic EPS of US$0.03, set against trailing 12 month revenue of US$159.6 million and a basic EPS loss of US$0.26. The company has seen quarterly revenue move from US$31.5 million in Q4 2024 to US$43.8 million in Q4 2025. Basic EPS has ranged from a loss of US$0.21 in Q1 2025 to US$0.06 in the year earlier quarter, leaving investors weighing solid top line progress against margins that are still under...

RAPT Therapeutics (RAPT) has drawn fresh attention after a sharp move in its share performance over the past 3 months. This has prompted investors to reassess the clinical stage biotech’s risk and reward profile. See our latest analysis for RAPT Therapeutics. At a share price of US$57.96, RAPT Therapeutics has shifted sharply over the past year, with a very large 1 year total shareholder return and a long term total shareholder return that remains negative. This suggests that recent momentum...

Ryerson Holding, now trading as NYSE:RYZ, has completed its merger with Olympic Steel. The combined company has introduced substantial changes to its executive leadership team and Board of Directors. The merger includes a stock ticker change and material amendments to Ryerson Holding's credit agreement. For you as an investor, this represents a meaningful reset for a metals service center business that now blends Ryerson Holding and Olympic Steel under the NYSE:RYZ ticker. Both companies...